23andMe Research Institute identifies genetic predictors for GLP-1 drug efficacy and side effects, helping personalize weight loss treatment. The discovery addresses why patients experience vastly different outcomes with medications like semaglutide
← News
Science Breakthroughs Science Breakthroughs Knowledge
Genetic predictors for GLP-1 weight loss efficacy and side effects identified
23andMe Research Institute Organization
Semaglutide, Tirzepatide Drugs analyzed
Variable Patient Outcomes Clinical challenge
Genetic Predictors Identified Breakthrough
Personalized Medicine advancement
Variable (Under 5% To Significant) outcome range